VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Li Discusses ALK Gene Mutation Tests

Tianhong Li, MD, PhD
Published: Monday, Aug 29, 2011

Tianhong (Tina) Li, MD, PhD, assistant professor, co-director of Phase I Program, UC Davis Cancer Center, mentions there are currently 4 tests available to detect an abnormal ALK gene. Patients with ALK-­­­positive non-small cell lung cancer are eligible to receive crizotinib (Xalkori).

The tests currently available include the FDA approved crizotinib companion diagnostic test Vysis ALK Break Apart FISH Probe Kit, real-time polymerase chain reaction (RT-PCR), molecular profiling testing, and immunohistochemistry or IHC.

The FDA approved Vysis test will be the first option for detection, but other options may also be used. As time progresses new tests need to be made available that are easier to use. The main drawbacks of the fluorescence in situ hybridization (FISH) tests are that they are very labor intensive and require special laboratories to complete. Research in the future will examine new testing options that require less work and are easier to conduct.
Tianhong (Tina) Li, MD, PhD, assistant professor, co-director of Phase I Program, UC Davis Cancer Center, mentions there are currently 4 tests available to detect an abnormal ALK gene. Patients with ALK-­­­positive non-small cell lung cancer are eligible to receive crizotinib (Xalkori).

The tests currently available include the FDA approved crizotinib companion diagnostic test Vysis ALK Break Apart FISH Probe Kit, real-time polymerase chain reaction (RT-PCR), molecular profiling testing, and immunohistochemistry or IHC.

The FDA approved Vysis test will be the first option for detection, but other options may also be used. As time progresses new tests need to be made available that are easier to use. The main drawbacks of the fluorescence in situ hybridization (FISH) tests are that they are very labor intensive and require special laboratories to complete. Research in the future will examine new testing options that require less work and are easier to conduct.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x